Source: Eur Respir J, 53 (4) 1900215; 10.1183/13993003.00215-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Helen Ashdown, Michael Steiner. Delivering high value therapies in COPD: the secret is in the marketing. Eur Respir J, 53 (4) 1900215; 10.1183/13993003.00215-2019

Member's Comments

No comment yet.

Related content which might interest you: Maintaining currency and improving utility of COPD guidelines: an achievable goal? Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009 Aiming for total control in asthma: an ineffective use of resources? Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005 The sustainability agenda and inhaled therapy: what do patients want? Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014 Prescription opioid use in advanced COPD: benefits, perils and controversies Source: Eur Respir J, 49 (6) 1700479; 10.1183/13993003.00479-2017 Year: 2017 Prescription opioid use in advanced COPD: benefits, perils and controversies Source: Eur Respir J, 49 (6) 1700690; 10.1183/13993003.00690-2017 Year: 2017 A lifeline for COPD: prevention strategy Source: Breathe 2010; 6: 204-209 Year: 2010 Optimising COPD prevention: what do the doctors need? Source: Annual Congress 2007 - Smoking and the lung Year: 2007 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 COPD self management: The impact of implementing self management plans & rescue medications across 3 hospitals Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD Year: 2012 Tele-education in asthma management. What are the benefits? Source: Annual Congress 2012 - Improving education for the healthcare team and patients Year: 2012 Adding biological markers to COPD categorisation schemes: a way towards more personalised care? Source: Eur Respir J 2016; 47:1601-1605 Year: 2016 Respiratory medicines for children: current evidence, unlicensed use and research priorities Source: Eur Respir J 2010; 35: 247-265 Year: 2010 Getting the rehabilitation message across: emerging barriers and positive health benefits Source: Eur Respir J 2009; 34: 2-4 Year: 2009 Pros: governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential Source: International Congress 2019 – Recent clinical advances in inhalation therapy Year: 2019 Realising the potential of mHealth to improve asthma and allergy care: how to shape the future Source: Eur Respir J, 49 (5) 1700447; 10.1183/13993003.00447-2017 Year: 2017 Doctors‘ compliance and adherence to treatment standards for asthma in Ukraine: who needs it more? Source: Eur Respir J 2005; 26: Suppl. 49, 381s Year: 2005 Cons - governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential Source: International Congress 2019 – Recent clinical advances in inhalation therapy Year: 2019 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016